The federal Food and Drug Administration approved new labeling Thursday for Pfizer Inc.'s Bextra drug to warn of possible serious skin reactions and heart-related problems for those who’ve experienced coronary bypass surgery. The federal regulatory agency said a new “black box” warning on the label will state that some patients have reported a serious and potentially fatal skin reaction, which the agency said is most likely to occur in the first two weeks of treatment.The agency said the label also would add a warning in bold type about possible heart attack, stroke and blood-clot problems in the legs and lungs of those undergoing coronary artery bypass graft surgery.
